BURLINGTON
BESREMi Pen cleared for polycythemia vera
- Sponsor
- PharmaEssentia Corporation $6446
- Drug
- BESREMi Pen · ropeginterferon alfa-2b-njft
- Indication
- polycythemia vera
FDA approved PharmaEssentia's BESREMi Pen (ropeginterferon alfa-2b-njft) for polycythemia vera treatment.
What this means
BESREMi is an injectable interferon drug that helps control excessive blood cell production in polycythemia vera, a rare blood cancer. FDA cleared a new pre-filled pen version of BESREMi, making it easier for patients to self-administer the treatment at home. The agency recommends "healthcare providers train patients on proper injection technique before initiating therapy with the BESREMi Pen.